Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma

Steven G. DuBois, Araz Marachelian, Hiroyuki Shimada et al.|Clinical Cancer Research|2018

Cited by 88